scholarly journals Single-Cell Microwell Platform Reveals Circulating Neural Cells as a Clinical Indicator for Patients with Blood-Brain Barrier Breakdown

Research ◽  
2021 ◽  
Vol 2021 ◽  
pp. 1-13
Author(s):  
Yu Zhang ◽  
Antony R. Warden ◽  
Khan Zara Ahmad ◽  
Yanlei Liu ◽  
Xijun He ◽  
...  
Keyword(s):  
Nervous System ◽  
Blood Brain Barrier ◽  
Artery Occlusion ◽  
Brain Barrier ◽  
Specific Marker ◽  
Neural Cells ◽  
Stroke Patients ◽  
Clinical Indicator ◽  
System Disease ◽  
Blood Brain

Central nervous system diseases commonly occur with the destruction of the blood-brain barrier. As a primary cause of morbidity and mortality, stroke remains unpredictable and lacks cellular biomarkers that accurately quantify its occurrence and development. Here, we identify NeuN+/CD45−/DAPI+ phenotype nonblood cells in the peripheral blood of mice subjected to middle cerebral artery occlusion (MCAO) and stroke patients. Since NeuN is a specific marker of neural cells, we term these newly identified cells as circulating neural cells (CNCs). We find that the enumeration of CNCs in the blood is significantly associated with the severity of brain damage in MCAO mice (p<0.05). Meanwhile, the number of CNCs is significantly higher in stroke patients than in negative subjects (p<0.0001). These findings suggest that the amount of CNCs in circulation may serve as a clinical indicator for the real-time prognosis and progression monitor of the occurrence and development of ischemic stroke and other nervous system disease.

Questioning the role of actinfree Gc-Globulin as actin scavenger in neurodegenerative central nervous system disease: Relationship to S-100B levels and blood–brain barrier function

2009 ◽  
Vol 400 (1-2) ◽  
pp. 86-90 ◽  
Author(s):  
Olav A. Gressner ◽  
Marie-Claire Schifflers ◽  
Philipp Kim ◽  
Leo Heuts ◽  
Birgit Lahme ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Blood Brain Barrier ◽  
Barrier Function ◽  
Central Nervous System Disease ◽  
Nervous System Disease ◽  
Brain Barrier ◽  
System Disease ◽  
Blood Brain

scholarly journals Gpr124 is essential for blood–brain barrier integrity in central nervous system disease

2017 ◽  
Vol 23 (4) ◽  
pp. 450-460 ◽  
Author(s):  
Junlei Chang ◽  
Michael R Mancuso ◽  
Carolina Maier ◽  
Xibin Liang ◽  
Kanako Yuki ◽  
...  
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Blood Brain Barrier ◽  
Central Nervous System Disease ◽  
Nervous System Disease ◽  
Brain Barrier ◽  
Barrier Integrity ◽  
System Disease ◽  
Blood Brain ◽  
Blood Brain Barrier Integrity

Liposomes: Novel Drug Delivery Approach for Targeting Parkinson’s Disease

2020 ◽  
Vol 26 (37) ◽  
pp. 4721-4737 ◽  
Author(s):  
Bhumika Kumar ◽  
Mukesh Pandey ◽  
Faheem H. Pottoo ◽  
Faizana Fayaz ◽  
Anjali Sharma ◽  
...  
Keyword(s):  
Parkinson’S Disease ◽  
Drug Delivery ◽  
Parkinson's Disease ◽  
Side Effects ◽  
Blood Brain Barrier ◽  
Brain Barrier ◽  
Brain Targeting ◽  
Neural Cells ◽  
Blood Brain ◽  
The Brain

Parkinson’s disease is one of the most severe progressive neurodegenerative disorders, having a mortifying effect on the health of millions of people around the globe. The neural cells producing dopamine in the substantia nigra of the brain die out. This leads to symptoms like hypokinesia, rigidity, bradykinesia, and rest tremor. Parkinsonism cannot be cured, but the symptoms can be reduced with the intervention of medicinal drugs, surgical treatments, and physical therapies. Delivering drugs to the brain for treating Parkinson’s disease is very challenging. The blood-brain barrier acts as a highly selective semi-permeable barrier, which refrains the drug from reaching the brain. Conventional drug delivery systems used for Parkinson’s disease do not readily cross the blood barrier and further lead to several side-effects. Recent advancements in drug delivery technologies have facilitated drug delivery to the brain without flooding the bloodstream and by directly targeting the neurons. In the era of Nanotherapeutics, liposomes are an efficient drug delivery option for brain targeting. Liposomes facilitate the passage of drugs across the blood-brain barrier, enhances the efficacy of the drugs, and minimize the side effects related to it. The review aims at providing a broad updated view of the liposomes, which can be used for targeting Parkinson’s disease.

scholarly journals Central nervous system delivery of molecules across the blood-brain barrier

2021 ◽  
pp. 104952
Author(s):  
Fabien Gosselet ◽  
Rodrigo Azevedo Loiola ◽  
Anna Roig ◽  
Anna Rosell ◽  
Maxime Culot
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Blood Brain Barrier ◽  
Brain Barrier ◽  
Blood Brain

Active Transport of High-Affinity Choline and Nicotine Analogs into the Central Nervous System by the Blood-Brain Barrier Choline Transporter

2002 ◽  
Vol 304 (3) ◽  
pp. 1268-1274 ◽  
Author(s):  
David D. Allen ◽  
Paul R. Lockman ◽  
Karen E. Roder ◽  
Linda P. Dwoskin ◽  
Peter A. Crooks
Keyword(s):  
Central Nervous System ◽  
Nervous System ◽  
Blood Brain Barrier ◽  
Active Transport ◽  
Brain Barrier ◽  
Choline Transporter ◽  
High Affinity ◽  
Blood Brain ◽  
The Central Nervous System ◽  
Nicotine Analogs
Sign in / Sign up

Export Citation Format

Share Document